

## How a 'Regulatory Dead Zone' May Be Holding Up Copycat Insulin

January 14, 2019

### ATTORNEYS

Landmon, Chad

Andrew Dunn

*BioPharma Dive*

### PRACTICE AREAS

FDA

Axinn partner Chad Landmon was quoted in the *BioPharma Dive* article, "How a 'Regulatory Dead Zone' May Be Holding Up Copycat Insulin."

Click [here](#) to access the article.